• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经导管动脉栓塞增强了原位肝癌大鼠模型中程序性细胞死亡配体 1 的表达并影响 CD8T 淋巴细胞的细胞毒性。

Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model.

机构信息

Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Suzhou, 215006, China.

Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, China.

出版信息

Cardiovasc Intervent Radiol. 2024 Oct;47(10):1372-1381. doi: 10.1007/s00270-024-03813-x. Epub 2024 Aug 5.

DOI:10.1007/s00270-024-03813-x
PMID:39103638
Abstract

PURPOSE

To investigate the influence of transarterial embolization (TAE) on programmed cell death-ligand 1(PD-L1) expression and CD8T tumour infiltrative lymphocyte cytotoxicity in the Sprague-Dawley (SD) rat model of hepatocellular carcinoma (HCC).

MATERIALS AND METHODS

An orthotopic HCC model was established in twenty SD rats treated with TAE (lipiodol, n = 10) or sham (normal saline, n = 10) using homologous N1S1 hepatoma cells. Rats were euthanized 1 week after embolization. Flow cytometry was used to assess the proportion of CD4T, CD8T and programmed cell death-1(PD-1) CD8T lymphocytes in the spleens and tumours. Distribution of CD8T, granzyme-BCD8T lymphocytes and PD-L1 cells was assessed by immunohistochemistry (IHC) or multiplex IHC. p value < 0.05 was considered statistically significant.

RESULTS

The CD4/CD8 ratio and PD-1CD8 T lymphocytes exhibited higher values in TAE-treated tumours compared to sham-treated tumours (p = 0.021 and p = 0.071, respectively). Conversely, the number of CD8T lymphocytes was decreased in TAE-treated tumours (p = 0.043), especially in the central region (p = 0.045). However, more CD8T lymphocytes were found infiltrating the marginal region than central region in TAE-treated tumours (p = 0.046). The proportion of granzyme-BCD8T lymphocytes and the PD-L1 positive areas was elevated in tumours that treated with TAE (p all < 0.05). There was a negative correlation between PD-L1 expression and the number of infiltration of CD8 T lymphocytes (p = 0.036).

CONCLUSIONS

Immune cells are distributed unevenly in the tumours after TAE. The intrinsic induction state of the tumour after embolization may be insufficient to elicit a maximal response to PD-1/PD-L1 inhibitors.

摘要

目的

研究经肝动脉栓塞术(TAE)对肝癌(HCC)Sprague-Dawley(SD)大鼠模型中程序性死亡配体 1(PD-L1)表达和 CD8+T 肿瘤浸润淋巴细胞细胞毒性的影响。

材料和方法

使用同源 N1S1 肝癌细胞,在 20 只 SD 大鼠中建立原位 HCC 模型,分别采用 TAE(碘油,n=10)或假手术(生理盐水,n=10)治疗。栓塞后 1 周处死大鼠。流式细胞术检测脾脏和肿瘤中 CD4+T、CD8+T 和程序性死亡-1(PD-1)+CD8+T 淋巴细胞的比例。免疫组化(IHC)或多重免疫组化检测 CD8+T、颗粒酶 B+CD8+T 淋巴细胞和 PD-L1 细胞的分布。p 值<0.05 为差异有统计学意义。

结果

与假手术组相比,TAE 治疗组肿瘤中的 CD4/CD8 比值和 PD-1+CD8+T 淋巴细胞比例更高(p=0.021 和 p=0.071)。相反,TAE 治疗组肿瘤中 CD8+T 淋巴细胞数量减少(p=0.043),尤其是在中央区域(p=0.045)。然而,在 TAE 治疗组肿瘤的边缘区域浸润的 CD8+T 淋巴细胞多于中央区域(p=0.046)。TAE 治疗组肿瘤中颗粒酶 B+CD8+T 淋巴细胞的比例和 PD-L1 阳性面积增加(p 均<0.05)。PD-L1 表达与 CD8+T 淋巴细胞浸润数量呈负相关(p=0.036)。

结论

TAE 后肿瘤内免疫细胞分布不均匀。栓塞后肿瘤的内在诱导状态可能不足以引起对 PD-1/PD-L1 抑制剂的最大反应。

相似文献

1
Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model.经导管动脉栓塞增强了原位肝癌大鼠模型中程序性细胞死亡配体 1 的表达并影响 CD8T 淋巴细胞的细胞毒性。
Cardiovasc Intervent Radiol. 2024 Oct;47(10):1372-1381. doi: 10.1007/s00270-024-03813-x. Epub 2024 Aug 5.
2
Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer.使用无机磷酸盐结合剂进行经动脉栓塞调节肝癌大鼠模型中免疫和血管生成相关因子
J Vasc Interv Radiol. 2025 Feb;36(2):320-331.e9. doi: 10.1016/j.jvir.2024.10.010. Epub 2024 Oct 19.
3
Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation.肝动脉栓塞增强原位大鼠肝细胞癌模型中程序性细胞死亡蛋白1配体1的表达:体内和体外实验
J Vasc Interv Radiol. 2020 Sep;31(9):1475-1482.e2. doi: 10.1016/j.jvir.2020.03.023. Epub 2020 Aug 14.
4
Transarterial Embolization Modulates the Immune Response within Target and Nontarget Hepatocellular Carcinomas in a Rat Model.经动脉栓塞调节大鼠模型中靶区和非靶区肝细胞癌内的免疫反应。
Radiology. 2022 Apr;303(1):215-225. doi: 10.1148/radiol.211028. Epub 2022 Jan 11.
5
Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.SIRT7 缺失通过 MEF2D 调控程序性细胞死亡配体 1 增加肝癌细胞中检查点抑制剂的疗效。
Gastroenterology. 2020 Feb;158(3):664-678.e24. doi: 10.1053/j.gastro.2019.10.025. Epub 2019 Oct 31.
6
Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.肿瘤相关巨噬细胞中程序性死亡配体 1 蛋白的优先表达及其在肝癌免疫治疗中的潜在作用。
Int J Mol Sci. 2021 Apr 29;22(9):4710. doi: 10.3390/ijms22094710.
7
Hepatic Arterial Bland Embolization Increases Th17 Cell Infiltration in a Syngeneic Rat Model of Hepatocellular Carcinoma.肝动脉 Bland 栓塞术增加了同源大鼠肝癌模型中 Th17 细胞的浸润。
Cardiovasc Intervent Radiol. 2020 Feb;43(2):311-321. doi: 10.1007/s00270-019-02343-1. Epub 2019 Oct 7.
8
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.骨桥蛋白诱导集落刺激因子 1 信号破坏肿瘤相关巨噬细胞的迁移,使肝细胞癌对抗 PD-L1 阻断敏感。
Gut. 2019 Sep;68(9):1653-1666. doi: 10.1136/gutjnl-2019-318419. Epub 2019 Mar 22.
9
Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.免疫反应对肝细胞癌结局的影响:与血管形成的关联。
Hepatology. 2020 Dec;72(6):1987-1999. doi: 10.1002/hep.31206. Epub 2020 Oct 20.
10
Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model.经动脉栓塞联合靶向缺氧诱导因子-1α的RNA干扰治疗肝细胞癌:大鼠模型的初步研究
J Cancer Res Clin Oncol. 2017 Feb;143(2):199-207. doi: 10.1007/s00432-016-2237-x. Epub 2016 Sep 16.

引用本文的文献

1
Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma.联合治疗可降低晚期肝细胞癌经动脉化疗栓塞的耐药性。
World J Clin Oncol. 2025 Aug 24;16(8):109419. doi: 10.5306/wjco.v16.i8.109419.
2
The efficacy of transarterial chemoembolization combined with helical iodine-125 seed implant, lenvatinib and PD-1 inhibitors in patients with hepatocellular carcinoma complicated by main portal vein tumor thrombus: a retrospective study.经动脉化疗栓塞联合螺旋碘-125粒子植入、仑伐替尼及PD-1抑制剂治疗合并门静脉主干癌栓的肝细胞癌患者的疗效:一项回顾性研究
Front Oncol. 2025 May 8;15:1514375. doi: 10.3389/fonc.2025.1514375. eCollection 2025.
3

本文引用的文献

1
The cancer-immunity cycle: Indication, genotype, and immunotype.癌症免疫周期:指征、基因型和免疫型。
Immunity. 2023 Oct 10;56(10):2188-2205. doi: 10.1016/j.immuni.2023.09.011.
2
TREM2 macrophages suppress CD8 T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma.TREM2 巨噬细胞抑制肝癌经动脉化疗栓塞术后 CD8+T 细胞浸润。
J Hepatol. 2023 Jul;79(1):126-140. doi: 10.1016/j.jhep.2023.02.032. Epub 2023 Mar 6.
3
High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
Invited Commentary on Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8 + T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model.
关于经动脉栓塞增强原位肝癌大鼠模型中程序性细胞死亡配体1表达并影响CD8 + T淋巴细胞细胞毒性的特邀评论
Cardiovasc Intervent Radiol. 2024 Oct;47(10):1382-1383. doi: 10.1007/s00270-024-03861-3. Epub 2024 Sep 24.
高血清白细胞介素-6与阿替利珠单抗和贝伐单抗在不可切除肝细胞癌中的临床获益降低相关。
JHEP Rep. 2023 Jan 16;5(4):100672. doi: 10.1016/j.jhepr.2023.100672. eCollection 2023 Apr.
4
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).经动脉化疗栓塞术联合 PD-(L)1 抑制剂和分子靶向治疗肝癌(CHANCE001)。
Signal Transduct Target Ther. 2023 Feb 8;8(1):58. doi: 10.1038/s41392-022-01235-0.
5
Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.经动脉化疗栓塞联合免疫检查点抑制剂加酪氨酸激酶抑制剂与免疫检查点抑制剂加酪氨酸激酶抑制剂治疗晚期肝细胞癌的比较
J Hepatocell Carcinoma. 2022 Nov 30;9:1217-1228. doi: 10.2147/JHC.S386672. eCollection 2022.
6
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.炎症和非炎症 HCC 分类:一种修正的免疫基因组分类。
Gut. 2023 Jan;72(1):129-140. doi: 10.1136/gutjnl-2021-325918. Epub 2022 Feb 23.
7
Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma.经动脉化疗栓塞联合免疫检查点抑制剂和酪氨酸激酶抑制剂治疗肝细胞癌的安全性和有效性
Front Oncol. 2022 Jan 13;11:657512. doi: 10.3389/fonc.2021.657512. eCollection 2021.
8
Transarterial Embolization Modulates the Immune Response within Target and Nontarget Hepatocellular Carcinomas in a Rat Model.经动脉栓塞调节大鼠模型中靶区和非靶区肝细胞癌内的免疫反应。
Radiology. 2022 Apr;303(1):215-225. doi: 10.1148/radiol.211028. Epub 2022 Jan 11.
9
Harnessing cytokines and chemokines for cancer therapy.利用细胞因子和趋化因子进行癌症治疗。
Nat Rev Clin Oncol. 2022 Apr;19(4):237-253. doi: 10.1038/s41571-021-00588-9. Epub 2022 Jan 7.
10
IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma.白细胞介素-6/信号转导子和转录激活子3是肝细胞癌颇具前景的治疗靶点。
Front Oncol. 2021 Dec 15;11:760971. doi: 10.3389/fonc.2021.760971. eCollection 2021.